Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01485536 · ClinicalTrials.gov registry record · Phase 2
A Study of the HSP90 Inhibitor AUY922
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT01485536: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01485536 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01485536, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if AUY922 can help to control refractory or recurrent lymphoma. The safety of AUY922 will also be studied. AUY922 is designed to block tumor growth by blocking a protein.
Interventions
- DRUG AUY922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01485536
The ClinicalTrials.gov registry entry for NCT01485536 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AUY922 is the first listed.
NCT01485536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01485536 about?
NCT01485536 is a clinical study titled "A Study of the HSP90 Inhibitor AUY922". The goal of this clinical research study is to learn if AUY922 can help to control refractory or recurrent lymphoma. The safety of AUY922 will also be studied. AUY922 is designed to block tumor growth by blocking a protein.
What is the current status of trial NCT01485536?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2012-08. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01485536?
The interventions under investigation include: AUY922 (DRUG).
Who is sponsoring clinical trial NCT01485536?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.